Financial Results for quarter and year ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Astal Laboratories (formerly Macro International) reported FY26 consolidated revenue of Rs 24,935 lakhs, a massive 287% jump from Rs 6,436 lakhs in FY25, driven by the acquisition of Sriven Pharmachem India Pvt Ltd as a wholly-owned subsidiary. Standalone revenue grew 139% to Rs 15,519 lakhs. Consolidated PAT rose 65% to Rs 1,471 lakhs, while standalone PAT declined 9% to Rs 812 lakhs. Share capital increased from Rs 985 lakhs to Rs 4,223 lakhs due to fresh equity issuance. The company operates in pharmaceutical bulk drugs. This was a revised filing correcting a typographical error in the original submission. Auditors gave an unmodified clean opinion.
The massive revenue growth on consolidation reflects the newly acquired subsidiary's contribution. However, standalone PAT decline and negative operating cashflows of Rs 1,760 lakhs (consolidated) and Rs 308 lakhs (standalone) indicate cash burn concerns despite profitability on paper.